Revealing the effect of CETP inhibition in cardiovascular disease
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mendelian randomization studies have provided accumulating evidence against the observational results that high levels of HDL-C are protective against CHD risk.
“MR studies have provided accumulating evidence against the observational results above.136–140”
From Mendelian randomization (2022) · cites this paper as [138]
The fact that similar estimates are seen in this regard for a wide variety of non-overlapping sets of instruments constructed to match pharmaceutical agents for LDL cholesterol lowering adds robustness to the interpretation.
“The fact that similar estimates are seen in this regard for a wide variety of non-overlapping sets of instruments constructed to match pharmaceutical agents for LDL cholesterol lowering adds robustness to the interpretation.112”
From Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): explanation and elaboration. (2021) · cites this paper as [112]
This difference seen between estimates relating to lifetime differences and shorter term cholesterol lowering is anticipated from the known cumulative effect of lipids on atherosclerotic coronary disease.
“This difference seen between estimates relating to lifetime differences and shorter term cholesterol lowering is anticipated from the known cumulative effect of lipids on atherosclerotic coronary disease.112”
From Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): explanation and elaboration. (2021) · cites this paper as [112]
The long term effect of lowered low density lipoprotein (LDL) cholesterol can be estimated from early life onwards by MR and is double the effect estimate derived from randomised trials.
“Conversely, the long term effect of lowered low density lipoprotein (LDL) cholesterol can be estimated from early life onwards by MR and is double the effect estimate derived from randomised trials.”
From Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): explanation and elaboration. (2021) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 56
- Authors
- Holmes, M. V., & Smith, G. D.
- Affiliations
- National Institute for Health and Care Research (GB)
- Corresponding author
- Holmes, Michael V.
- Venue
- Nature Reviews Cardiology
- Published
- 2017-10-05
- Volume
- 14
- Issue
- 11
- Pages
- 635-636
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC5644574
- OpenAlex
- W2763860064
- Cited by
- 56
- References
- 10
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 6
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Funders
- University of Oxford
- University of Bristol (MC_UU_12013/1)
- Medical Research Council (MC_UU_12013, MCUU12013/1)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- cholesteryl ester transfer protein, CETP inhibitors, coronary artery disease, HDL cholesterol, non-HDL cholesterol, cardiovascular risk, REVEAL trial, drug safety
- MeSH terms
- Anticholesteremic Agents, Cardiovascular Diseases, Humans, Cholesterol, HDL, Biomarkers, Randomized Controlled Trials as Topic, Dyslipidemias, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
